BACCARANI, MICHELE
BACCARANI, MICHELE
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
18F-FDG PET early after radiotherapy in lymphoma patients.
2004 CASTELLUCCI P; ZINZANI P; NANNI C; FARSAD M; MORETTI A; ALINARI L; BATTISTA G; PETTINATO C; MARENGO M; BOSCHI S; CANINI R; BACCARANI M.; MONETTI N; FANTI S.
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL)
2011 Anna Ferrari, Ilaria Iacobucci, Marco Sazzini, Annalisa Lonetti, Alessio Boattini, Cristina Papayannidis, Mariachiara Abbenante, Vilma Mantovani, Viviana Guadagnuolo, Federica Cattina, Elena Marasco, Emanuela Ottaviani, Stefania Paolini, Domenico Girelli, Simona Soverini, Michele Baccarani, Giovanni Martinelli
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
2008 Zinzani P.L.; Tani M.; Fanti S.; Stefoni V.; Musuraca G.; Vitolo U.; Perrotti A.; Fina M.; Derenzini E.; Baccarani M.
A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML)
2014 Cristina Papayannidis, Stefania Paolini, Barbara Lama, Emanuela Ottaviani, Federica Salmi, Ilaria Iacobucci, Antonio Curti, Daniela Cilloni, Sarah Parisi, Giuseppe Saglio, Renato Fanin, Fortunato Morabito, Maria Pantaleo, Pier Luigi Lollini, Michele Baccarani, Giovanni Martinelli
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
2007 Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F.
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
2012 Zinzani P.L.; Tani M.; Pulsoni A.; De Renzo A.; Stefoni V.; Broccoli A.; Montini G.C.; Fina M.; Pellegrini C.; Gandolfi L.; Cavalieri E.; Torelli F.; Scopinaro F.; Argnani L.; Quirini F.; Derenzini E.; Rossi M.; Pileri S.; Fanti S.; Baccarani M.
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia
2011 IACOBUCCI I.; SAZZINI M.; GARAGNANI P.; FERRARI A.; BOATTINI A.; LONETTI A.; PAPAYANNIDIS C.; MANTOVANI V.; MARASCO E.; OTTAVIANI E.; SOVERINI S.; GIRELLI D.; LUISELLI D.; VIGNETTI M.; BACCARANI M.; MARTINELLI G.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line
2017 Castagnetti, Fausto; Di Raimondo, Francesco; De Vivo, Antonio; Spitaleri, Antonio; Gugliotta, Gabriele; Fabbiano, Francesco; Capodanno, Isabella; Mannina, Donato; Salvucci, Marzia; Antolino, Agostino; Marasca, Roberto; Musso, Maurizio; Crugnola, Monica; Impera, Stefana; Trabacchi, Elena; Musolino, Caterina; Cavazzini, Francesco; Mineo, Giuseppe; Tosi, Patrizia; Tomaselli, Carmela; Rizzo, Michele; Siragusa, Sergio; Fogli, Miriam; Ragionieri, Riccardo; Zironi, Alessandro; Soverini, Simona; Martinelli, Giovanni; Cavo, Michele; Vigneri, Paolo; Stagno, Fabio; Rosti, Gianantonio; Baccarani, Michele
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
2007 Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M.
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia
2016 Baccarani, Michele; Gugliotta, Gabriele; Castagnetti, Fausto; Soverini, Simona; Rosti, Gianantonio
A review of the European LeukemiaNet recommendations for the management of CML
2015 Baccarani, Michele; Castagnetti, Fausto; Gugliotta, Gabriele; Rosti, Gianantonio
A risk prediction score for invasive mold disease in patients with hematological malignancies
2013 Stanzani M;Lewis RE;Fiacchini M;Ricci P;Tumietto F;Viale P;Ambretti S;Baccarani M;Cavo M;Vianelli N
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.
2011 Malagola M; Skert C; Vignetti M; Piciocchi A; Martinelli G; Alimena G; Mecucci C; Testoni N; Iacobucci I; Clavio M; Gobbi M; Candoni A; Damiani D; Bocchia M; Lauria F; Zaccaria A; Mazza P; Visani G; Peli A; Colombi C; Cancelli V; Mancini M; Fo R; Martelli M; Cantore N; Raimondo FD; Petrini M; de Fabritiis P; Fioritoni G; Nobile F; Fabbiano F; Specchia G; Baccarani M; Coco FL; Amadori S; Mandelli F; Russo D.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
2005 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
2006 Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation.
2004 ARPINATI M; CHIRUMBOLO G; URBINI B; BONIFAZI F; BANDINI G; SAUNTHARARAJAH Y; ZAGNOLI A; STANZANI M; FALCIONI S; PERRONE G; TURA S; BACCARANI M.; RONDELLI D.
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.
2007 Curti A; Aluigi M; Pandolfi S; Ferri E; Isidori A; Salvestrini V; Durelli I; Horenstein AL; Fiore F; Massaia M; Piccioli M; Pileri SA; Zavatto E; D'Addio A; Baccarani M; Lemoli RM.
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications
2008 Luatti S.; Marzocchi G.; Ottaviani E.; Baldazzi C.; Stacchini M.; Gamberini C.; Salmi F.; Martinelli G.; Baccarani M.; Testoni N.
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
2012 S Luatti; F Castagnetti; G Marzocchi; C Baldazzi; G Gugliotta; I Iacobucci; G Specchia; L Zanatta; G Rege-Cambrin; M Mancini; E Abruzzese; A Zaccaria; M G Grimoldi; A Gozzetti; G Ameli; M A Capucci; G Palka; P Bernasconi; F Palandri; F Pane; G Saglio; G Martinelli; G Rosti; M Baccarani; N Testoni; on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia
1998 Damiani D.; Michieli M.; Ermacora A.; Russo D.; Fanin R.; Zaja F.; Baraldo M.; Pea F.; Furlanut M.; Baccarani M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| 18F-FDG PET early after radiotherapy in lymphoma patients. | CASTELLUCCI P; ZINZANI P; NANNI C; FARSAD M; MORETTI A; ALINARI L; BATTISTA G; PETTINATO C; MAREN...GO M; BOSCHI S; CANINI R; BACCARANI M.; MONETTI N; FANTI S. | 2004-01-01 | CANCER BIOTHERAPY & RADIOPHARMACEUTICALS | - | 1.01 Articolo in rivista | - |
| A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) | Anna Ferrari, Ilaria Iacobucci, Marco Sazzini, Annalisa Lonetti, Alessio Boattini, Cristina Papay...annidis, Mariachiara Abbenante, Vilma Mantovani, Viviana Guadagnuolo, Federica Cattina, Elena Marasco, Emanuela Ottaviani, Stefania Paolini, Domenico Girelli, Simona Soverini, Michele Baccarani, Giovanni Martinelli | 2011-01-01 | CANCER RESEARCH | - | 1.06 Abstract in rivista | - |
| A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma | Zinzani P.L.; Tani M.; Fanti S.; Stefoni V.; Musuraca G.; Vitolo U.; Perrotti A.; Fina M.; Derenz...ini E.; Baccarani M. | 2008-01-01 | CANCER | - | 1.01 Articolo in rivista | - |
| A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML) | Cristina Papayannidis, Stefania Paolini, Barbara Lama, Emanuela Ottaviani, Federica Salmi, Ilaria... Iacobucci, Antonio Curti, Daniela Cilloni, Sarah Parisi, Giuseppe Saglio, Renato Fanin, Fortunato Morabito, Maria Pantaleo, Pier Luigi Lollini, Michele Baccarani, Giovanni Martinelli | 2014-01-01 | CANCER RESEARCH | - | 1.06 Abstract in rivista | - |
| A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. | Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballer...o D; Ben-Yehuda D; Giles F. | 2007-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. | Zinzani P.L.; Tani M.; Pulsoni A.; De Renzo A.; Stefoni V.; Broccoli A.; Montini G.C.; Fina M.; P...ellegrini C.; Gandolfi L.; Cavalieri E.; Torelli F.; Scopinaro F.; Argnani L.; Quirini F.; Derenzini E.; Rossi M.; Pileri S.; Fanti S.; Baccarani M. | 2012-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
| A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia | IACOBUCCI I.; SAZZINI M.; GARAGNANI P.; FERRARI A.; BOATTINI A.; LONETTI A.; PAPAYANNIDIS C.; MAN...TOVANI V.; MARASCO E.; OTTAVIANI E.; SOVERINI S.; GIRELLI D.; LUISELLI D.; VIGNETTI M.; BACCARANI M.; MARTINELLI G. | 2011-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| A population-based study of chronic myeloid leukemia patients treated with imatinib in first line | Castagnetti, Fausto; Di Raimondo, Francesco; De Vivo, Antonio; Spitaleri, Antonio; Gugliotta, Gab...riele; Fabbiano, Francesco; Capodanno, Isabella; Mannina, Donato; Salvucci, Marzia; Antolino, Agostino; Marasca, Roberto; Musso, Maurizio; Crugnola, Monica; Impera, Stefana; Trabacchi, Elena; Musolino, Caterina; Cavazzini, Francesco; Mineo, Giuseppe; Tosi, Patrizia; Tomaselli, Carmela; Rizzo, Michele; Siragusa, Sergio; Fogli, Miriam; Ragionieri, Riccardo; Zironi, Alessandro; Soverini, Simona; Martinelli, Giovanni; Cavo, Michele; Vigneri, Paolo; Stagno, Fabio; Rosti, Gianantonio; Baccarani, Michele | 2017-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. | Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini... D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia | Baccarani, Michele; Gugliotta, Gabriele; Castagnetti, Fausto; Soverini, Simona; Rosti, Gianantonio | 2016-01-01 | - | Springer Verlag | 2.01 Capitolo / saggio in libro | - |
| A review of the European LeukemiaNet recommendations for the management of CML | Baccarani, Michele; Castagnetti, Fausto; Gugliotta, Gabriele; Rosti, Gianantonio | 2015-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| A risk prediction score for invasive mold disease in patients with hematological malignancies | Stanzani M;Lewis RE;Fiacchini M;Ricci P;Tumietto F;Viale P;Ambretti S;Baccarani M;Cavo M;Vianelli N | 2013-01-01 | PLOS ONE | - | 1.01 Articolo in rivista | mold PREDICTION RULE.pdf |
| A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. | Malagola M; Skert C; Vignetti M; Piciocchi A; Martinelli G; Alimena G; Mecucci C; Testoni N; Iaco...bucci I; Clavio M; Gobbi M; Candoni A; Damiani D; Bocchia M; Lauria F; Zaccaria A; Mazza P; Visani G; Peli A; Colombi C; Cancelli V; Mancini M; Fo R; Martelli M; Cantore N; Raimondo FD; Petrini M; de Fabritiis P; Fioritoni G; Nobile F; Fabbiano F; Specchia G; Baccarani M; Coco FL; Amadori S; Mandelli F; Russo D. | 2011-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia | Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagn...etti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M. | 2005-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. | Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cill...oni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. | ARPINATI M; CHIRUMBOLO G; URBINI B; BONIFAZI F; BANDINI G; SAUNTHARARAJAH Y; ZAGNOLI A; STANZANI ...M; FALCIONI S; PERRONE G; TURA S; BACCARANI M.; RONDELLI D. | 2004-01-01 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. |
Curti A; Aluigi M; Pandolfi S; Ferri E; Isidori A; Salvestrini V; Durelli I; Horenstein AL; Fior...e F; Massaia M; Piccioli M; Pileri SA; Zavatto E; D'Addio A; Baccarani M; Lemoli RM. |
2007-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications | Luatti S.; Marzocchi G.; Ottaviani E.; Baldazzi C.; Stacchini M.; Gamberini C.; Salmi F.; Martine...lli G.; Baccarani M.; Testoni N. | 2008-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis | S Luatti; F Castagnetti; G Marzocchi; C Baldazzi; G Gugliotta; I Iacobucci; G Specchia; L Zanatta...; G Rege-Cambrin; M Mancini; E Abruzzese; A Zaccaria; M G Grimoldi; A Gozzetti; G Ameli; M A Capucci; G Palka; P Bernasconi; F Palandri; F Pane; G Saglio; G Martinelli; G Rosti; M Baccarani; N Testoni; on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML | 2012-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia | Damiani D.; Michieli M.; Ermacora A.; Russo D.; Fanin R.; Zaja F.; Baraldo M.; Pea F.; Furlanut M....; Baccarani M. | 1998-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |